Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi ( (SNY) ) just unveiled an announcement.
At its mixed Annual General Meeting on April 29, 2026 in Paris, Sanofi’s shareholders approved all resolutions, including the appointment of former Merck chief executive Belén Garijo to the board, with Garijo set to take over as Sanofi’s Chief Executive Officer on May 1, 2026. Her mandate underscores the board’s focus on sharpening execution, capital allocation and converting the company’s scientific output into more durable financial performance.
Shareholders also validated the 2025 financial statements and an ordinary dividend of €4.12 per share, payable on May 7, 2026, while renewing the board terms of Christophe Babule and Jean‑Paul Kress and appointing Orange CEO Christel Heydemann as an independent director. Following the departures of Paul Hudson and Patrick Kron, Sanofi reconfigured key board committees, leaving a 16‑member board with high independence and gender diversity, signalling governance continuity alongside a leadership reset that could shape the group’s next phase of strategic transformation.
The most recent analyst rating on (SNY) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a research-driven, AI‑enabled biopharmaceutical group that develops medicines and vaccines targeting immune system pathways, with a focus on major diseases in immunology and oncology. Listed in Paris and on Nasdaq, the company pursues growth through an innovation-led pipeline aimed at improving health outcomes for millions of patients worldwide.
Average Trading Volume: 3,796,606
Technical Sentiment Signal: Hold
Current Market Cap: $109.5B
For an in-depth examination of SNY stock, go to TipRanks’ Overview page.